RELATLIMAB AND NIVOLUMAB

Brand name:

• Opdualag®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Submission sponsor:

BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD

Condition/indication:
(therapeutic use)

• Melanoma

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC Submission type:

New listing (Matters arising/Matters outstanding)

Comment:

Please see RELATLIMAB AND NIVOLUMAB link in Related medicines below.

Other PBAC consideration:

• RELATLIMAB WITH NIVOLUMAB
• RELATLIMAB AND NIVOLUMAB

Submission received for:

July 2023 PBAC meeting

Opportunity for consumer comment:

Open 29/03/2023 and close 24/05/2023 (see PBS Website)

PBAC meeting:

Held on 05/07/2023

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

Awaiting lodgement from pharmaceutical company

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable